I see, BUT this does NOT apply to the Anavex Phase 2b/3 trial since Anavex did not select participants who had sigma-1 wild type receptors and APOE3 alleles and only treat with the high 50 mg per day target dose.
In general the only selection criteria for the best responders was a baseline MMSE of greater than or equal to 20 which is quite common for virtually all Alzheimer's trials, because once the brain starts to shrink due to dead brain cells no treatment can bring back dead brain cells.
The Anavex Phase 2b/3 trial was very well designed and executed.
Expect very very good results from Anavex's successful Phase 2b/3 trial.
I think your explanation of selection bias is an appropriate prologue to Investor's repetitive posts regarding the likely success of any future Phase 3 AD trial (if needed). Anavex has developed a fundamental understanding of subgroup factors that would help assure success. They aren't about to use random variables, or mistaken assumptions, in a selection process; unlike the competition, they have been doing the hard and groundbreaking fundamental research into the mechanisms of Alzheimer's Disease.
Market Data 
Markets 
AI
